BeiGene Announces approval for its three oncology products in China

Date: 2020-12-29   Author: Saipriya Iyer  Category: #news

BeiGene Announces approval for its three oncology products in China

BeiGene Ltd., one of the leading Chinese commercial-stage biotechnology firms focused on commercializing and developing innovative medicines, has reportedly announced that it has received approval from the NHSA (China National Healthcare Security Administration) for three of its oncology medicines.

Sources cite that the NHSA has included anti-PD-1 antibody tislelizumab, XGEVA® (120-mg denosumab), and BTK inhibitor BRUKINSA® (zanubrutinib) to its updated NRDL (National Reimbursement Drug List).

Speaking on which, Xiaobin Wu, Ph.D., President of BeiGene said that the NRDL’s addition of tislelizumab, BRUKINSA, and XGEVA would help expand access to these top-quality oncology treatments in the nation and ease the financial burden for patients suffering from cancer and their families. The company believes that the approval could have a profound impact on patients in the nation that is accountable for one-fourth of the world’s cancer patients each year.

He added that the company is appreciative of its team’s efforts and its partnership in developing and commercializing these medicines, and understands that this accomplishment wouldn’t have been possible without the nation’s commitment to high-quality treatments and innovation through ongoing drug reform and the Healthy China initiative.

With these NRDL inclusions, the company is making substantial strides towards the  its mission, which at its core is to strengthen access to and enhance impactful innovative medicines’ affordability for patients worldwide, Dr. Wu said, while adding that the company is looking forward to more exciting progress on this endeavor.

XGEVA® from BeiGene’s partnership with Amgen is included in one approved indication. It has received conditional approval in the nation as a treatment for SREs (Skeletal-related events) in patients with bone metastases from solid tumors and in patients with MM (Multiple Myelona), which wasn’t eligible for 2020 NRDL considerations as it was authorized after the cut-off date.

For the record, BeiGene is a biopharmaceutical firm focused on introducing molecularly targeted and immuno-oncology drug candidates for treating cancer.

Source credit - https://www.businesswire.com/news/home/20201227005018/en/BeiGene-Announces-Inclusion-of-Three-Innovative-Oncology-Products-in-China-National-Reimbursement-Drug-List-NRDL



About Author


Saipriya Iyer linkdin-boxtwitter

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

Post Recommendents

Leaded Disc MOV Market 2021-2027 Detailed Analysis and Growth Strategies, Regional and Recent Scenario Analysis

Author: Sachin Pashte

Decoding Covid-19 impact on Leaded Disc MOV market over 2021-2027, with report inclusions as growth determinants, challenges, and revenue generating prospects.

The recent study on Leaded Disc MOV market is compiled with an objective to a...


Plastic Pre-Filled Syringes Sales Market Share, Growth, Statistics, by Application, Production, Revenue & Forecast to 2027

Author: Sachin Pashte

Market Study Report adds a new research on Global Plastic Pre-Filled Syringes Sales Market for the period of 2021-2027 that shows the growth of the market is rising at a Steady CAGR to 2027.

The recent study on Plastic Pre-Filled Syringe...


Clindamycin Phosphate and Benzoyl Peroxide Sales market to showcase strong CAGR between 2027 and 2027

Author: Sachin Pashte

Primary aspects discussed in Clindamycin Phosphate and Benzoyl Peroxide Sales market research report: profit margins, pricing models, production and consumption volume, demand and supply trends, COVID-19 impact.

The recent study on Clind...